Search

Your search keyword '"Hullsiek, Katherine H."' showing total 2 results
Start Over Author "Hullsiek, Katherine H." Database Supplemental Index
2 results on '"Hullsiek, Katherine H."'

1. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

Author

Li, Jonathan Z., Paredes, Roger, Ribaudo, Heather J., Svarovskaia, Evguenia S., Kozal, Michael J., Hullsiek, Katherine H., Miller, Michael D., Bangsberg, David R., and Kuritzkes, Daniel R.

Abstract

To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations.

Published
2012
Full Text
View/download PDF

2. Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

Author

Skipper, Caleb P., Atukunda, Mucunguzi, Stadelman, Anna, Engen, Nicole W., Bangdiwala, Ananta S., Hullsiek, Katherine H., Abassi, Mahsa, Rhein, Joshua, Nicol, Melanie R., Laker, Eva, Williams, Darlisha A., Mannino, Raphael, Matkovits, Theresa, Meya, David B., and Boulware, David R.

Abstract

Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors of cryptococcosis (n= 9 per cohort).

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results